1. A molecule that binds to the ectodomain of the receptor for human vascular endothelial growth factor (VEGF receptor), where the molecule is antagonistic to the activity of the VEGF receptor. The molecule of claim 1, wherein said molecule binds to an Ig-like domain of a human VEGF receptor. The molecule of claim 2, wherein said Ig-like domain is not responsible for binding of the ligand to the VEGF receptor. The molecule of claim 2, wherein said Ig-like domain is responsible for binding the ligand to the VEGF receptor. The molecule according to claim 1, wherein said molecule does not block the interaction between the VEGF receptor and the VEGF receptor ligand. The molecule of claim 1, wherein said molecule blocks the interaction between the VEGF receptor and the VEGF receptor ligand. The molecule of claim 1, wherein said molecule does not prevent dimerization of the VEGF receptor. The molecule of claim 1, wherein said molecule prevents dimerization of the VEGF receptor. The molecule of claim 1, wherein said molecule prevents interaction between the ectodomain region closest to the membrane from each VEGF receptor protomer. The molecule of claim 9, wherein said interaction is homotypic. The molecule of claim 9, wherein said interaction is heterotypic. The molecule of claim 9, wherein said ectodomain region closest to the membrane is the 7th Ig-like domain (D7) of the VEGF receptor. The molecule of claim 12, wherein said molecule binds to the following consensus sequence of the VEGF receptor domain D7: L / I XR Φ XXXD / E XG (SEQ ID NO: 158), where L is leucine, I is isoleucine, R is arginine, Φ is a hydrophobic amino acid, D is aspartic acid, E is glutamic acid, G is gly1. Молекула, которая связывается с эктодоменом рецептора фактора роста эндотелия сосудов человека (VEGF-рецептора), где указанная молекула проявляет антагонизм в отношении активности VEGF рецептора.2. Молекула по п.1, где указанная молекула связывается с Ig-подобным доменом VEGF-рецептора человека.3
